Frontiers in oncology · 2025
Volatile organic compounds in exhaled human breath for the diagnosis of malignant pleural mesothelioma: a meta-analysis.
СтатьяСистематический обзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhao Tingting, Hu Xiao, Peng Minghua, Wei Wei, Fu Ninghua, Chen Chen, Chen Zhenguang
Аннотация
OBJECTIVE: Malignant pleural mesothelioma (MPM) is a relatively rare thoracic tumor with a high mortality rate, making early diagnosis and treatment challenging. The present study evaluated the utility of exhaled volatile organic compounds (VOCs) in diagnosing MPM.
METHODS: The Cochrane Library, PubMed, EMBASE, and Web of Science were systematically searched for clinical trials assessing the diagnostic ability of VOCs for MPM through August 30, 2024. Quality was evaluated using the QUADAS-2 tool. A meta-analysis was performed with a bivariate model for sensitivity and specificity using Stata MP 17.0 software.
RESULTS: Eight trials with 859 subjects were included. VOCs were found to have a pooled sensitivity of 0.86 (95% confidence interval [CI] 0.75-0.93), a pooled specificity of 0.73 (95% CI 0.58-0.84), and an area under the curve (AUC) of 0.88 (95% CI 0.85-0.90) in differentiating MPM patients from healthy controls. In addition VOCs had a pooled sensitivity of 0.89 (95% CI 0.83-0.93), a pooled specificity of 0.79 (95% CI 0.57-0.91), and an AUC of 0.91 (95% CI 0.88-0.93) in differentiating MPM patients from asymptomatic individuals formerly exposed to asbestos (AEx).
CONCLUSIONS: Although the utility of VOCs in diagnosing MPM varied among clinical trials, VOCs in exhaled human breath may have a potential role in the diagnosis of MPM. Large-scale randomized clinical trials are warranted.
METHODS: The Cochrane Library, PubMed, EMBASE, and Web of Science were systematically searched for clinical trials assessing the diagnostic ability of VOCs for MPM through August 30, 2024. Quality was evaluated using the QUADAS-2 tool. A meta-analysis was performed with a bivariate model for sensitivity and specificity using Stata MP 17.0 software.
RESULTS: Eight trials with 859 subjects were included. VOCs were found to have a pooled sensitivity of 0.86 (95% confidence interval [CI] 0.75-0.93), a pooled specificity of 0.73 (95% CI 0.58-0.84), and an area under the curve (AUC) of 0.88 (95% CI 0.85-0.90) in differentiating MPM patients from healthy controls. In addition VOCs had a pooled sensitivity of 0.89 (95% CI 0.83-0.93), a pooled specificity of 0.79 (95% CI 0.57-0.91), and an AUC of 0.91 (95% CI 0.88-0.93) in differentiating MPM patients from asymptomatic individuals formerly exposed to asbestos (AEx).
CONCLUSIONS: Although the utility of VOCs in diagnosing MPM varied among clinical trials, VOCs in exhaled human breath may have a potential role in the diagnosis of MPM. Large-scale randomized clinical trials are warranted.